FDA Investigating Safety Concerns with Unapproved Dental Devices

The agency's actions follow reports of serious complications with use of these devices.

I Stock 1357109020
iStock

The U.S. Food and Drug Administration (FDA) is evaluating safety concerns with the use of certain dental devices that are fixed (non-removable) palatal expanders used on adults to remodel the jaw or to treat conditions.

The devices of concern include:

  • Anterior Growth Guidance Appliance (AGGA) and Fixed Anterior Growth Guidance Appliance (FAGGA),
  • Anterior Remodeling Appliance (ARA) and Fixed Anterior Remodeling Appliance (FARA),
  • Osseo-Restoration Appliance (ORA) and Fixed Osseo-Restoration Appliance (FORA), and
  • Any other similar device types.

The FDA is aware of these devices being used to treat conditions such as obstructive sleep apnea (OSA) and temporomandibular joint disorder (TMD) of the jaw, and to remodel the jaw in adults. However, the safety and effectiveness of these devices intended for these uses have not been established, and these devices are not cleared or approved by the FDA.

The FDA is also aware of reports of serious complications with use of these devices. The FDA is asking patients, caregivers, and health care providers to report any complications with these devices to the FDA. Prompt reporting of adverse events can help the FDA identify and better understand the risks associated with medical devices. The FDA is working to evaluate information from all available sources to provide additional information on this issue.

Recommendations for Patients, Caregivers and Health Care Providers

  • Be aware the FDA is evaluating safety concerns with the use of certain dental devices, such as the AGGA, FAGGA, ARA, FARA, ORA, and FORA. 
  • Be aware the safety and effectiveness of these devices to treat conditions such as OSA and TMD, or to remodel the jaw in adults have not been established. These devices intended for these uses have not been cleared or approved by the FDA. 
  • Consult with a dental professional for problems or concerns with a dental device. Use of the AGGA, FAGGA, ARA, FARA, ORA, or FORA dental devices on adults may result in serious complications which may require intervention, such as:
    • Chronic pain
    • Tooth dislocation 
    • Flared teeth
    • Uneven bite
    • Difficulty eating
    • Damaged gums
    • Exposed roots
    • Bone erosion
    • Tooth loss 
  • Report any problems with these devices to the FDA. 

Device Description

Palatal expanders are dental devices typically used to widen the roof of the mouth (palate) to make room for crowded teeth. Palatal expanders are generally used during orthodontic treatment for children and adolescents whose upper jaw bones are not yet fused. At this time, the FDA is not aware of safety concerns related to orthodontic use of palatal expanders in children and adolescentsExternal Link Disclaimer.

In contrast, an adult’s upper jaw bones are fused, and when a fixed palatal expansion device applies force, the palate is resistant to expansion. If forces are applied incorrectly to the teeth, serious complications can occur including chronic pain, tooth dislocation, flared teeth, uneven bite, difficulty eating, damaged gums, exposed roots, bone erosion, and tooth loss. These complications typically require intervention by a health care professional.

The safety and effectiveness of fixed (non-removable) palatal expanders being used to treat conditions such as OSA and TMD, or to remodel the jaw in adults have not been established and these devices have not been cleared or approved by the FDA.

FDA Actions

The FDA is informing patients, caregivers, and health care providers about safety concerns with the use of certain dental devices on adults, such as the AGGA, FAGGA, ARA, FARA, ORA, FORA, and any similar device types. The FDA is identifying and contacting responsible entities to communicate our concerns. The FDA plans to investigate potential violations and take action if appropriate. The FDA is working to further evaluate all available information about the issue. We will continue to monitor complaints and reports of adverse events associated with this issue.

The FDA will keep patients, caregivers, and health care providers informed as significant information becomes available.

More in News